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Abstract:  This  last  article  in  a  three-part  series  on  approved  medications  for  managing 
fibromyalgia syndrome (FMS) reviews pregabalin (Lyrica®). Pregabalin was the first drug 
approved for FMS management and, as an anticonvulsant, differs from the other approved 
agents that are antidepressants. Pregabalin inhibits presynaptic excitatory neurotransmitter 
release by blocking a2d calcium channels. Five randomized, placebo-controlled trials have 
demonstrated pregabalin reduces pain and improves sleep and health-related quality of life 
in FMS patients. While indicated dosing is 300–450 mg divided twice daily, initial dosing of 
25–50 mg at night is recommended owing to side effects including somnolence, dizziness, 
and cognitive dysfunction. Since side effects such as weight gain and peripheral edema are 
dose-related, uptitration in weekly increments based on tolerability and therapeutic response is 
recommended. Due to its lack of protein binding and negligible hepatic metabolism, pregabalin 
can be safely combined with other medications and used in patients with renal failure when 
the dose is appropriate. Pregabalin may worsen sedation when combined with central nervous 
system depressants. Pregabalin should be discontinued gradually. Pregabalin-treated patients 
should be monitored for the emergence or worsening of depression, suicidal thoughts or 
behavior. Pregabalin in combination with the other approved medications may be synergistic 
in treating FMS.
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Introduction
Fibromyalgia syndrome (FMS) is a disorder of chronic widespread pain (CWP) 
and tender points associated with a number of other symptoms including fatigue, 
nonrestorative sleep, depression, anxiety, and stiffness.1 FMS is a common disorder 
occurring around the world, with published prevalence rates of up to 5%.2 However, 
these rates likely underestimate the true prevalence of FMS since they are based 
on criteria that do not lead to the identification of half of clinically diagnosed FMS 
patients.3 FMS is a significant cause of morbidity, resulting in high costs due to health 
care utilization and disability comparable to those seen in patients with rheumatoid 
arthritis.4 Evidence-based management guidelines recommend a multidisciplinary 
treatment approach that combines pharmacologic and nonpharmacologic modalities 
individually tailored according to patient symptoms to effectively manage FMS symp-
toms.5 Nonpharmacologic treatments include graduated aerobic and resistance exercise, 
education and cognitive-behavioral therapies. There are currently three pharmacologic 
therapies indicated by the United States (US) Food and Drug Administration (FDA) 
for the management of FMS: duloxetine (Cymbalta®), milnacipran (Savella™) and Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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pregabalin (Lyrica®). Previous articles in this series have 
reviewed duloxetine and milnacipran.6,7 This article will 
focus on the pharmacology, mechanism of action, efficacy, 
safety, and tolerability of pregabalin in the hopes it will aid 
providers in caring for FMS patients.
Review of pharmacology, mode  
of action and pharmacokinetics  
of pregabalin
On June 21, 2007, pregabalin became the first medication 
to receive FDA approval for the management of FMS. 
Pregabalin had previously been approved for treating diabetic 
peripheral neuropathic pain (DPNP), post-herpetic neuralgia 
(PHN), and as adjunctive therapy for adult patients with 
partial onset seizures.8 Pregabalin differs from the other two 
indicated FMS medications by the fact that it is classified 
as an anticonvulsant and not an antidepressant. Pregabalin, 
and the closely related drug gabapentin (Neurontin®), is a 
structural analog of the neurotransmitter g-aminobutyric 
acid (GABA). Pregabalin is an a2d calcium channel antago-
nist that inhibits presynaptic neurotransmitter release. The 
pharmacologic actions of pregabalin are restricted to neurons, 
as pregabalin has no effect on blood pressure or heart rate 
even at high dosages, unlike the vascular calcium channel 
blockers. While its mechanism of action is not completely 
understood, the analgesic, anticonvulsant, and anxiolytic 
actions of pregabalin are thought to result from decreasing 
central nervous system (CNS) concentrations of excitatory 
neurotransmitters including glutamate and substance P.9,10 
FMS patients are known to have increased CNS levels of 
substance P and glutamate,11,12 and increased levels of these 
neurotransmitters have been implicated in the process of 
central pain amplification that is thought to underlie FMS.13 
Related to its inhibition of nerve signaling, pregabalin can 
have sedative effects. Because of this, use of pregabalin 
with other CNS depressants should be limited and patients 
should be warned not to operate heavy machinery until they 
determine how pregabalin will affect them.
Pregabalin has numerous favorable pharmacokinetic prop-
erties including negligible serum protein binding (limiting 
the possibility for displacing other drugs), negligible hepatic 
metabolism, and linear dosing kinetics.8 These properties 
limit drug–drug interactions, making pregabalin amenable 
to combination therapy, which is important in FMS manage-
ment since patients commonly require multiple medications 
to manage their symptoms. Pregabalin has a relatively short 
half-life (6.3 hours), necessitating twice-daily dosing to 
maintain plasma drug levels. However, many FMS patients 
complain of somnolence and dizziness as well as worsening 
of fatigue and cognitive dysfunction when pregabalin is 
taken during the day. The short half-life of pregabalin can be 
exploited to limit side effects during the day by dosing all or 
most of pregabalin with the evening meal or at bedtime when 
somnolence can be beneficial for improving sleep. Pregabalin 
absorption is altered by taking it with food, resulting in pro-
longation of time to maximum plasma concentration (Tmax) to 
3 hours and decreasing the maximum plasma concentration 
(Cmax) by 25%–30%.8 Since this can limit side effects, taking 
pregabalin with food is recommended.
Pregabalin efficacy studies
A recent meta-analysis that systematically analyzed the 
scientific literature identified five randomized, double-blind, 
placebo-controlled trials (RCTs) of pregabalin for the treat-
ment of FMS that met standardized criteria for validity 
and methodological quality,14 making pregabalin the most 
thoroughly studied of the FDA-approved therapies. All 
enrolled patients were required to meet American College 
of Rheumatology classification criteria for FMS and the 
primary endpoint for all the RCTs was improvement in pain 
symptoms.1 Pain was also the primary endpoint for FMS 
RCTs of duloxetine,6 whereas milnacipran used composite 
endpoints combining pain with global and physical function 
improvement.7 All pregabalin trials required FMS patients to 
have baseline visual analog scale (VAS) pain scores of $4 cm 
on a 10-cm scale, consistent with RCTs of duloxetine and 
milnacipran. Also consistent with duloxetine and milnacipran 
trials, FMS patients were excluded from pregabalin RCTs 
if they had evidence of inflammatory rheumatic disease, or 
clinically significant or unstable medical or psychological 
conditions. Patients were also excluded if they were applying 
for disability or engaged in litigation related to FMS. As in 
the RCTs for the other approved FMS drugs, the majority of 
patients in the pregabalin trials were middle-aged, Cauca-
sian women, making generalization of trial results to other 
genders or ethnic groups problematic. All trials also used 
twice-daily dosing with rapid uptitration of study medication, 
with patients typically reaching doses of 300 mg/day by the 
end of the first week and maximal study doses by the end of 
week 2. Since such rapid dose titration is not typically used 
in the clinic, withdrawal and adverse event (AE) rates seen in 
the RCTs may be higher than those observed clinically.
The first RCT published in 2005 was an 8-week trial that 
assessed 529 FMS patients equally divided to receive pla-
cebo or pregabalin at doses of 150, 300, and 450 mg divided 
twice daily.15 Only the 450-mg/day group met the primary Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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study endpoint, with significantly lower pain scores averaged 
over the last week (−0.93 on a 0–10 scale, P # 0.001) and 
significantly more patients with either a $30% or $50% 
improvement in baseline pain scores compared with placebo 
(48.4% vs 27.1%, P = 0.003 and 29% vs 13%, P = 0.003, 
respectively). It should be noted that a $30% improvement is 
considered the minimally clinically significant difference that 
can be measured, whereas a $50% improvement is consid-
ered a better measure of an improvement that is meaningful 
in the daily life of patients.16 Pregabalin treatment at 300 mg/
day or 450 mg/day was associated with statistically significant 
improvements in sleep quality, fatigue, and global impression 
of change (both patient and clinician reported). However, it 
should be noted that this trial used last observation carried 
forward (LOCF) to analyze the data. While a typical analytic 
method for RCTs, LOCF is a less conservative analysis than 
baseline observation carried forward (BOCF), which is 
required by the FDA for pain studies. LOCF allows the last 
data collected from patients who do not complete a trial to 
be used as endpoint data, whereas BOCF requires baseline 
data be used. This means that drug effects on noncomplet-
ing patients are included in analyses using LOCF but not in 
analyses using BOCF. Pregabalin effects were rapid, with 
improvements seen as early as the first week of treatment.
The second RCT published in March 2008 was a 13-week 
trial that assessed 748 FMS patients.17 Patients were random-
ized equally to receive either placebo or pregabalin at doses 
of 300, 450, or 600 mg divided twice daily. In addition to 
the primary endpoint evaluating pain improvement, the trial 
had a co-primary endpoint to evaluate pregabalin efficacy in 
managing global FMS symptoms by assessing improvement 
in the Patient Global Impression of Change (PGIC) and the 
Fibromyalgia Impact Questionnaire (FIQ) total score. The 
PGIC is a standard patient self-report questionnaire that mea-
sures change in patients’ overall status after drug treatment on 
a numeric rating scale ranging from 1 = ‘very much improved’ 
to 7 = ‘very much worse’, with 4 =  ‘no change.’18 The FIQ 
is a 20-item patient self-report instrument that quantifies 
the global impact of FMS by querying physical functioning, 
pain, fatigue, stiffness, morning tiredness, difficulty working 
(including housework), number of days patients ‘felt good’, 
and symptoms of depression and anxiety in the past week.19 
The FIQ yields a score from 0 to 100, with higher scores 
indicating more severe FMS. The second RCT met its primary 
pain endpoint, with all pregabalin treatment groups having 
statistically significant improvement in pain compared to 
placebo-treated groups. While patients in pregabalin-treated 
groups had significantly greater improvement in PGIC scores 
compared to those receiving the placebo, the study failed to 
reach both co-primary endpoints since none of the pregabalin 
groups had significant improvement in FIQ total scores com-
pared to placebo groups. As in the previously discussed RCT, 
all three pregabalin doses (300, 450, and 600 mg/day) were 
associated with statistically significant improvement in sleep 
quality. However, no statistically significant improvement was 
seen in symptoms of fatigue as in the previous trial.
The third FMS pregabalin trial, published in June 2008, 
was a 6-month trial that evaluated the efficacy and durability of 
pregabalin treatment of FMS pain.20 This RCT was conducted 
in a much different manner than all previous and subsequent 
FMS trials to date. In this trial, 1051 FMS patients were first 
assigned to a 6-week   open-label pregabalin-treatment period 
divided into an initial 3-week dose optimization phase fol-
lowed by a 3-week fixed-dose phase. Upon entering the dose 
optimization phase, an open-label baseline assessment was 
performed to quantify symptoms of pain (using a VAS) and 
fatigue (using the   Multidimensional Assessment of Fatigue, 
MAF),21 sleep quality (using the Medical Outcomes Study 
(MOS)-sleep scale),22 and overall health status (using the 
FIQ and the MOS 36-item short form survey instrument, 
SF-36).19,23 All FMS patients were then treated with pregaba-
lin at 150 mg/day divided twice daily for 3 days. After 3 days, 
drug tolerability was assessed. If tolerated, pregabalin dose 
was increased to 300 mg/day divided twice daily. If patients 
did not tolerate the drug, they were withdrawn from the trial. 
At the end of the first week, patients were assessed for efficacy 
and tolerability. Efficacy was determined by two criteria: 1) 
$50% reduction in pain VAS score from baseline and 2) 
self-rating of ‘much improved’ or ‘very much improved’ on 
the PGIC scale. If patients showed efficacy and tolerability, 
dosage was maintained at 300 mg/day throughout the end of 
the open-label phase. If patients failed to show efficacy but 
maintained tolerability, pregabalin dose was increased to 450 
mg/day for another week after which they were again assessed 
for efficacy and tolerability. Patients who then met efficacy 
and tolerability criteria were maintained on a 450-mg/day 
dose throughout the end of the open-label phase. Patients 
who did not meet efficacy but maintained tolerability had 
their dose increased to 600 mg/day. After 1 week, patients 
on 600 mg/day were again assessed for efficacy and toler-
ability and those who met efficacy and tolerability criteria 
were maintained on that dose throughout the open-label 
phase. Patients who did not tolerate drug were withdrawn 
from the trial. By the end of week 3, all patients remaining 
in the trial were being treated with pregabalin at doses of 
300, 450, or 600 mg/day. At this point, patients entered Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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a 3-week fixed-dose phase in which they were maintained 
on stable doses of pregabalin and were assessed each week 
for the drug’s efficacy. To be considered responders and 
enter the double-blind phase of the trial, patients had to 
meet both pain and PGIC efficacy criteria at week 4 or 5 
and also at week 6, and had to maintain drug tolerance. 
For the 6-month double-blind phase, half of responders in 
each dose group (300, 450, or 600 mg/day) were random-
ized to either continue pregabalin treatment at the same 
dose or receive treatment with placebo (after a 2–6 day 
taper depending on dosage group). All participants were 
then assessed at week 8 and every 4 weeks thereafter to 
evaluate efficacy using the pain VAS, MAF, MOS-Sleep 
Scale, FIQ, and SF-36. The primary outcome of the study 
was time to loss of therapeutic response (LTR) defined as 
either a worsening of pain VAS score to within 30% of the 
open-labeled baseline score at two consecutive visits in the 
double-blind phase (with the first of the two visits defining 
the time to LTR and the second used only for confirmation 
of LTR) or worsening of FMS symptoms that, in the judg-
ment of the investigator, necessitated alternate treatment. 
Secondary endpoints compared the difference in time to 
loss of response for other improved therapeutic outcomes 
as determined by a change in questionnaire scores indicat-
ing worsening of more than the minimally important clini-
cal difference (for the FIQ, MAF, MOS-Sleep Scale, and 
SF-36) or a score indicating less improvement than ‘much 
improved’ on the PGIC. The trial met its primary endpoint, 
with the time to LTR significantly longer for pregabalin 
versus placebo treatment (P , 0.0001). By day 19, half of 
the placebo group had LTR, whereas by the end of the trial 
more than half of the pregabalin group still had not lost 
response. At the end of the 6 month double-blind phase, 
68% of pregabalin-treated patients had maintained their 
therapeutic response compared to 39% of those treated 
with the placebo. When the individual pregabalin fixed-
dosage groups of 300, 450, and 600 mg/day were compared 
with their corresponding placebo groups, each pregabalin 
treatment group was associated with a significantly longer 
time to LRT. All secondary efficacy endpoints also dem-
onstrated significantly greater time to LTR for pregabalin 
compared to placebo treatment (P , 0.0001 for all), with 
median time to loss of response longer for pregabalin 
treatment as measured by the PGIC (126 vs 20 days), 
the FIQ (19 vs 14 days), the MOS-Sleep Scale (42 vs   
14 days), the MAF (119 vs 27 days), and SF-36 compo-
nent scores for physical (49 vs 15 days) and mental (42 vs   
14 days) function.
The fourth pregabalin FMS trial was a 14-week RTC 
that studied 745 patients, and was published in September 
2008.24 This trial has been criticized because it was preceded 
by a 1-week placebo run-in phase that excluded placebo 
responders, defined as patients with $30% decreases in VAS 
pain scores.25 However, trial results are felt by the author to 
be valid since exclusions occurred prior to randomization, 
few patients were excluded (19 total), and the results of 
the trial were accepted by the FDA in support of the FMS 
indication. As in the above-mentioned 13-week study, the 
primary outcome variable was improvement in endpoint 
mean VAS pain scores, with additional primary efficacy 
parameters including PGIC and FIQ total scores. Patients 
were randomized to receive placebo or pregabalin at doses of 
300, 450, or 600 mg/day divided twice daily. The fourth study 
met its primary endpoint, with all three pregabalin doses 
providing significantly greater improvement in endpoint 
pain scores compared to placebo. The proportion of patients 
with $30% or $50% decreases in mean pain scores from 
baseline to endpoint were significantly greater in all active 
treatment groups compared with placebo group patients. 
The $30% responder rate was 30% in the placebo group, 
42% in the 300-mg/day, 50% in the 450-mg/day, and 48% in 
the 600-mg/day pregabalin groups (P = 0.0172, P = 0.0002, 
and P = 0.0006, respectively), whereas the $50% responder 
rate was 15% in the placebo group, 24% in the 300-mg/day, 
27% for 450-mg/day, and 30% for 600-mg/day pregalin 
groups (P = 0.0372, P = 0.0038, P = 0.001, respectively). 
Contrary to the previous 13-week RCT, significantly greater 
improvement for both FIQ and PGIC scores were observed 
across all pregabalin treatment groups compared to the 
placebo groups, with the exception of the FIQ score in the 
300-mg/day pregabalin group. Consistent with previous 
trials, all pregabalin doses improved sleep quality but no 
improvements were seen in fatigue, depression, or anxiety 
symptoms at indicated doses.
The fifth pregabalin FMS RCT has not been published. 
However, a description and results are available online and 
were included as part of a meta-analysis that reviewed it and 
the other four pregabalin FMS RCTs from which trial infor-
mation can be obtained.14,26 This RCT was a standard 14-week 
parallel-group trial that randomized 747 FMS patients to treat-
ment with placebo or pregabalin at doses of 300, 450, and 600 
mg/day divided twice daily. The primary endpoint measure 
was the endpoint mean pain score derived from the subject’s 
daily pain diary, and a co-primary endpoint was PGIC score. 
Secondary endpoints included evaluations of the efficacy 
of pregabalin compared with placebo for improvement of Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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sleep, function, fatigue, health-related quality of life, and 
mood disturbance as determined by changes in scores on 
the MOS-Sleep Scale, FIQ, MAF, SF-36, and the Hospital 
Anxiety and Depression Scale (HADS),27 respectively. As 
in the fourth study, this trial included a 1-week placebo 
run-in phase to exclude placebo responders. In contrast to 
the other studies that were conducted exclusively within the 
US, this trial was conducted exclusively outside the US at 
73 centers in North America (Canada and Mexico), South 
America (Venezuela), Europe (Denmark, France, Germany, 
Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, and 
United Kingdom), Asia (India and Korea) and Australia, indi-
cating that its results may be more broadly applicable. While 
the primary trial endpoint was reached, only the 450-mg/
day treatment group experienced a statistically significant 
improvement in the endpoint mean pain score compared with 
placebo-treated subjects (P = 0.0132). As in previous trials, 
pregabalin-treated patients had significant improvement in 
sleep quality (all doses) and PGIC scores (450- and 600-mg/
day groups). Pregabalin at 450 mg/day was superior compared 
with placebo on the FIQ total score, and pregabalin at 450 and 
600 mg/day significantly improved SF-36 mental component 
scores. There were no statistically significant differences for 
the comparisons between pregabalin and placebo for MAF 
(fatigue) or HADS (anxiety and depression) scores.
Two recent meta-analyses have assessed the efficacy 
of pregabalin by analyzing the results from the five FMS 
trials described above.14,28 Both meta-analyses found that 
pregabalin treatment significantly reduced pain, improved 
sleep, and improved health-related quality of life in FMS 
patients over placebo. There were also statistically significant, 
but less robust, effects of pregabalin on reducing fatigue and 
anxiety symptoms, but no evidence was seen for improvement 
in depression symptoms. While the magnitude of beneficial 
effects was small, with effect sizes ranging from approxi-
mately 0.2 to 0.4 using Cohen’s categories, these effect sizes 
are similar to those seen for other analgesic medications felt 
to be effective in treating chronic pain conditions such as par-
acetamol or nonsteroidal anti-inflammatory drugs for treating 
osteoarthritis.29 Also, the therapeutic effect of pregabalin on 
pain was similar to that seen for other FMS treatments such 
as duloxetine30 and the combination of tramadol and acet-
aminophen.31 (While milnacipran likely has similar efficacy 
in treating FMS pain, there are currently no meta-analyses 
from which to obtain effect size data.) However, FMS 
patients typically experience numerous symptoms in addition 
to pain that can be equally or even more debilitating, and 
evidence-based FMS management guidelines recommend 
individualizing therapy based on associated symptoms to 
optimally manage FMS.5 Based on RCTs and clinical experi-
ence, pregabalin has been recommended for initial treatment 
of FMS patients with significant sleep complaints.32 While 
pregabalin may benefit FMS patients with anxiety, these 
patients should also be screened for depression, since anxiety 
and depression frequently coexist and pregabalin does not 
improve depressive symptoms. In FMS patients with coex-
isting anxiety and depression, duloxetine would likely be a 
better initial choice since it is indicated for treating all three 
conditions.33 However, FMS patients can be highly variable 
in the medications to which they respond and treatment 
recommendations should be considered rough guides rather 
than absolute rules.
Safety and tolerability  
of pregabalin
The best source for information on the safety and tolerability 
of pregabalin in FMS patients comes from two meta-
analyses.14,28 A large percentage of patients in the trials had 
at least one AE regardless of treatment (74% and 88% for 
placebo and pregabalin, respectively). However, few patients 
experienced a serious AE (2%), and serious AE rates did not 
differ between placebo and pregabalin treatment groups, 
supporting the safety of pregabalin treatment in FMS patients. 
Tolerability can be gauged by looking at the discontinuation 
rates observed in the trials. For the indicated FMS doses, no 
significant differences were seen in total discontinuation rates 
between placebo and pregabalin treatments. However, for 
discontinuations due to an AE, a dose-response relationship 
was found for pregabalin. While the risk was similar between 
placebo and pregabalin at 150 mg/day, relative risk for dis-
continuation was higher for pregabalin compared to placebo 
for all other doses and increased with dose (1.6, 1.9, and 
2.5 for 300, 450, and 600 mg/day, respectively). This is 
consistent with clinical observations that lower pregabalin 
doses are better tolerated, and use of the smallest effective 
dose is recommended.
Dizziness was the most common AE in the FMS trials, 
and all pregabalin doses were associated with increased 
relative risk for dizziness compared to placebo. A dose 
response relationship was seen for dizziness rates, with 
11% for placebo, 23% for 150 mg/day, 33% for 300 mg/day, 
43% for 450 mg/day, and 47% for 600 mg/day of pregaba-
lin. Somnolence was the second most common AE, with a 
5% rate for placebo and rates of 20%–23% for pregabalin 
doses of 150–600 mg/day. Pregabalin use was also associ-
ated with a twofold increased risk for gaining more than 7% Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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in body weight, and this risk occurred regardless of dose. 
While pregabalin use was also associated with an increased 
peripheral edema rate (6% for indicated pregabalin doses vs 
2% for placebo), edema occurred independent of weight gain. 
Pregabalin-treated patients also had higher rates of fatigue 
(averaging 7.6% for indicated pregabalin doses vs 3.5% 
for placebo) and cognitive dysfunction (6% for indicated 
pregabalin doses vs 1% for placebo). To limit occurrence of 
all these AEs, pregabalin dosing primarily at bedtime, with a 
smaller dose taken on awakening only if needed for symptom 
control during the day, is recommended. Taking pregabalin 
with food may also limit AEs by decreasing the Cmax and 
increasing the Tmax.8 Since nausea is a frequent AE seen in 
FMS patients treated with duloxetine and milnacipran,33,34 
it is important to realize pregabalin-treated patients had no 
increase in nausea rates compared to placebo-treated patients 
(9% vs 8%, respectively), making pregabalin the best choice 
for FMS patients with gastrointestinal complaints.
All antiepileptic drugs (AED), including pregabalin, warn 
in their prescribing information that use may be associated 
with increased suicide risk. The concern for increased suicide 
risk comes from a pooled analysis of 199 placebo-controlled 
clinical trials of 11 different AEDs involving 43,892 patients 
aged 5 years and older conducted by the FDA.35 The analysis 
showed that patients treated with AEDs had approximately 
twice the risk of suicidal thinking or behavior compared to 
patients randomized to placebo, with an odds ratio (OR) of 
1.80 (95% confidence interval [CI]: 1.24, 2.66). However, only 
two drugs, topiramate and lamotrigine, had OR-associated 
confidence intervals that did not cross 1.0 and were therefore 
associated with a statistically significant increased risk. Also, 
statistically significant suicide risk with AED treatment was 
only seen in epileptic patients (OR 3.53, 95% CI: 1.28, 12.10). 
Neither psychiatric patients (OR 1.51, 95% CI: 0.95, 2.45) nor 
other patient groups (OR 1.87, 95% CI: 0.81, 4.76) treated 
with AEDs had statistically significant increased suicide risk. 
While suicide risk may be increased by AED treatment, the 
FDA did not feel the risk was sufficient to warrant a black 
boxed warning in the prescribing information of pregabalin.8 
This indicates the risk for suicidality with pregabalin treatment 
of nonepileptic FMS patients is likely to be low. However, 
since the risk to individual patients cannot be predicted, it 
is recommended that patients treated with an AED for any 
indication be monitored for the emergence or worsening of 
depression, suicidal thoughts or behavior, and/or any unusual 
changes in mood or behavior. It is important to note that both 
duloxetine and milnacipran have black box warnings for 
suicidalilty in their prescribing information.33,34
Pregabalin’s place in FMS  
treatment
Owing to the heterogeneity of FMS patients, an individualized 
treatment regimen based on associated symptoms is 
recommended to optimize management.5 The FIBRO 
mnemonic can be used to recall commonly associated FMS 
symptoms and individualize treatment; ‘F’ for fatigue and 
fibrofog (cognitive dysfunction), ‘I’ for insomnia (poor sleep), 
‘B’ for blues (depression and/or anxiety), ‘R’ for rigidity 
(stiffness of muscles and/or joints) and ‘O’ for ow! (pain and 
work disability).32 While all FDA-indicated FMS treatments 
have similar efficacy in improving pain, meta-analyses of FMS 
RCTs show pregabalin is unique in its ability to also improve 
sleep.14,28 Pregabalin has been shown to decrease sleep latency 
and modify sleep architecture by enhancing slow-wave sleep, 
making it a particularly good choice for FMS patients with 
sleep complaints.36 Pregabalin has also been shown to improve 
anxiety symptoms in FMS RCT meta-analyses.14,28 Analyses of 
pregabalin treatment in patients with generalized anxiety disor-
der indicate pregabalin has a moderate effect in treating anxiety 
symptoms that is comparable to other anxiolytics, including the 
serotonin and norepinephrine reuptake inhibitors (SNRIs), at 
doses of 200 mg/day and higher.37,38 FMS patients have a five-
fold increased rate of anxiety disorders compared to controls,39 
indicating the anxiolytic effect of pregabalin may benefit 
many FMS patients. However, pregabalin does not improve 
symptoms of depressed mood in FMS patients.14,28 Owing to 
the high concurrence of depressive and anxiety disorders, it is 
recommended that anxious FMS patients be screened for the 
presence of depression and, if depressive symptoms are present, 
duloxetine be considered as first-line since it is indicated to 
treat major depressive disorder, generalized anxiety disorder, 
and FMS.33 Also, since pregabalin use has been associated 
with worsening cognitive dysfunction (‘fibrofog’),14,28 consid-
eration should be given for using milnacipran first-line in FMS 
patients with baseline cognitive dysfunction since milnacipran 
can improve cognition.7 At appropriate doses, pregabalin 
can be used in patients with any degree of renal impairment 
including dialysis patients, making it an excellent choice for 
FMS patients with renal impairment.8 An important difference 
between pregabalin and the other indicated FMS medications 
is that pregabalin use is not associated with nausea, making 
pregabalin an excellent choice for FMS patients with baseline 
gastrointestinal complaints such as irritable bowel syndrome. 
Pregabalin use has also not been associated with headache,8 
making it a better choice for FMS patients with migraine than 
the other two indicated drugs (duloxetine and milnacipran), 
which often cause headache.33,34Journal of Pain Research 2010:3 submit your manuscript | www.dovepress.com
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Pregabalin has numerous favorable pharmacokinetic 
properties including no serum protein binding and negligible 
hepatic metabolism that make it safe for use in combination 
with other drugs.8 Since the proposed mechanisms of 
action differ between pregabalin and the other indicated 
FMS drugs, with pregabalin thought to decrease excitatory 
nerve signaling and duloxetine and milnacipran thought to 
increase inhibitor signaling, it is reasonable to hypothesize 
that combination therapy may be synergistic. A combination 
trial of the a2d  calcium channel antagonist gabapentin and the 
SNRI venlafaxine for individuals with diabetic neuropathy 
supports this theory.40 This trial showed that the combina-
tion of gabapentin and venlafaxine improved symptoms of 
pain, fatigue, mood disturbance, and insomnia in patients 
with neuropathic pain who had not responded to gabapentin 
monotherapy previously. The potential for synergy may 
have significant clinical implications, as currently indicated 
FMS therapies typically have only mild efficacy in treating 
FMS symptoms.28,30 Clinical experience has shown that the 
combination of pregabalin at bedtime with duloxetine or 
milnacipran upon awakening can often provide therapeutic 
efficacy in FMS patients who have failed monotherapy uti-
lizing lower, often better tolerated, drug doses. Randomized 
combination trials are needed to better understand the risks 
and benefits of combination therapy in treating FMS patients. 
In the interim, combination therapy should be used cautiously 
owing to the potential for additive adverse effects.
Conclusions and key points
1.  Pregabalin was the first FDA drug approved drug for the 
management of FMS syndrome.
2.  Pregabalin is an a2d  calcium channel antagonist catego-
rized as an antiepileptic, thought to work by decreasing 
excitatory nerve signaling.
3.  Pregabalin has favorable pharmacokinetic properties 
including no serum protein binding, negligible hepatic 
metabolism and linear dosing kinetics.
4.  The safety and efficacy of pregabalin in managing FMS 
have been demonstrated by five RCTs involving over 
3800 FMS patients.
5.  Pregabalin can reduce symptoms of pain, anxiety, and 
fatigue, and can improve global function and sleep quality 
in FMS patients.
6.  Adverse events associated with pregabalin use include 
dizziness, somnolence, weight gain, peripheral edema, 
fatigue, and cognitive dysfunction.
7.  Pregabalin-treated patients should be monitored for the 
emergence or worsening of depression, suicidal thoughts 
or behavior, and/or any unusual changes in mood or 
behavior.
8.  The combination of pregabalin at bedtime and either 
duloxetine or milnacipran on awakening may be 
synergistic in managing FMS symptoms, but clinical 
trials using combination therapy are needed to identify 
potential additive adverse events.
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